- Home
- JRS vs LXEO Comparison
JRS vs LXEO Comparison
Compare JRS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- LXEO
- Stock Information
- Founded
- JRS 2001
- LXEO 2017
- Country
- JRS United States
- LXEO United States
- Employees
- JRS N/A
- LXEO N/A
- Industry
- JRS Finance/Investors Services
- LXEO
- Sector
- JRS Finance
- LXEO
- Exchange
- JRS Nasdaq
- LXEO Nasdaq
- Market Cap
- JRS 267.5M
- LXEO 252.4M
- IPO Year
- JRS N/A
- LXEO 2023
- Fundamental
- Price
- JRS $8.22
- LXEO $6.36
- Analyst Decision
- JRS
- LXEO Strong Buy
- Analyst Count
- JRS 0
- LXEO 5
- Target Price
- JRS N/A
- LXEO $23.80
- AVG Volume (30 Days)
- JRS 86.6K
- LXEO 251.9K
- Earning Date
- JRS 01-01-0001
- LXEO 12-24-2024
- Dividend Yield
- JRS 8.87%
- LXEO N/A
- EPS Growth
- JRS N/A
- LXEO N/A
- EPS
- JRS N/A
- LXEO N/A
- Revenue
- JRS N/A
- LXEO N/A
- Revenue This Year
- JRS N/A
- LXEO N/A
- Revenue Next Year
- JRS N/A
- LXEO N/A
- P/E Ratio
- JRS N/A
- LXEO N/A
- Revenue Growth
- JRS N/A
- LXEO N/A
- 52 Week Low
- JRS $5.95
- LXEO $5.77
- 52 Week High
- JRS $8.00
- LXEO $22.33
- Technical
- Relative Strength Index (RSI)
- JRS 18.92
- LXEO 39.36
- Support Level
- JRS $9.44
- LXEO $6.78
- Resistance Level
- JRS $9.48
- LXEO $7.40
- Average True Range (ATR)
- JRS 0.16
- LXEO 0.70
- MACD
- JRS -0.13
- LXEO -0.05
- Stochastic Oscillator
- JRS 0.00
- LXEO 4.80
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.